First Frontline Immunotherapy Approved for Gastric Cancer

On April 16, the U.S. Food and Drug Administration (FDA) approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for frontline treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Nivolumab is the first immunotherapy approved as a first-line treatment for this patient population. The decision was supported by … Continue reading First Frontline Immunotherapy Approved for Gastric Cancer